Epidermal Growth Factor Receptor (EGFR)
For patients with non-small cell lung cancer who have EGFR mutations and brain metastases, progression-free survival was improved with afatinib compared to chemotherapy.
LUX-Lung 7 Trials Shows Afatinib Achieves Better Response Than Gefitinib in Patients With EGFR-mutated Lung CancerJanuary 05, 2016
In the global, randomized, open-label phase IIb LUX-Lung 7 trial, efficacy across a range of clinically relevant end points, such as progression-free survival, time-to-treatment failure, and objective response rate, was significantly improved with afatinib vs. gefitinib.
Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies, was found to be clinically active in patients with advanced colorectal cancer that had become anti-EGFR therapy resistant.
A recent study has found that, within the Asian population, the frequency of epidermal growth factor receptor mutations associated with other demographic and clinical characteristics is higher than previously reported, even in patients with a history of smoking.
The investigational drug AZD9291, a third-generation epidermal growth factor receptor (EGFR) inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
The FDA has granted orphan drug designation to a cancer stem cell inhibitor known as VS-6063, or defactinib, for use in the treatment of mesothelioma, a rare form of lung cancer.
Which patients, if any, should receive prophylactic antibiotics when starting therapy with epidermal growth factor receptor (EGFR) inhibitors?
Lung cancer in women who have never smoked is more frequently associated with EGFR mutations and estrogen receptor overexpression, according to a new study.
Patients with epidermal growth factor receptor (EGFR) exon 20 insertions have similar clinical characteristics to those with common EGFR mutations but have a poorer response, according to a recent study.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|